VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_15-vv-00632
Package ID: USCOURTS-cofc-1_15-vv-00632
Petitioner: Nicholle M. Cielencki
Filed: 2015-12-22
Decided: 2016-05-02
Vaccine: Pneumovax 23
Vaccination date: 2012-06-19
Condition: 
Outcome: dismissed
Award amount USD: 

AI-assisted case summary:
Nicholle M. Cielencki filed a petition alleging injury from a Pneumovax 23 vaccine received on June 19, 2012. The court issued an order to show cause because Pneumovax 23 is a polysaccharide vaccine not covered by the National Vaccine Injury Compensation Program. The petitioner's counsel was granted multiple extensions to amend the petition to allege injury from a Program-covered vaccine or show cause why the case should not be dismissed. Despite these extensions, the petitioner failed to file a response or provide evidence of a Program-covered vaccine. The court noted that the petitioner had severed contact with her counsel, making it difficult to obtain necessary authorizations. Ultimately, the case was dismissed for failure to state a claim upon which relief can be granted, as the vaccine was not covered by the Program, and also for failure to prosecute due to the lack of response to the court's orders.

Theory of causation field:
unclear

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_15-vv-00632-0
Date issued/filed: 2016-05-02
Pages: 4
Docket text: PUBLIC DECISION (Originally filed: 12/22/2015) regarding 14 DECISION of Special Master ( Signed by Chief Special Master Nora Beth Dorsey.)(mpj) Copy to parties.
--------------------------------------------------------------------------------
Case 1:15-vv-00632-UNJ Document 16 Filed 05/02/16 Page 1 of 4
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 15-632V
Filed: December 22, 2015
* * * * * * * * * * * * * * * * * * * * * * * * * * * *
NICHOLLE M. CIELENCKI, *
*
Petitioner, * Dismissal; Not a Covered Vaccine;
v. * Pneumovax 23; Failure to Prosecute
*
SECRETARY OF HEALTH *
AND HUMAN SERVICES, *
*
Respondent. *
*
* * * * * * * * * * * * * * * * * * * * * * * * * * * *
Rodger Pirnie Doyle, Jr., Kenney Shelton Liptak Nowak, LLP, Buffalo, NY, for petitioner.
Heather Lynn Pearlman, U.S. Department of Justice, Washington, DC, for respondent.
DECISION1
On June 19, 2015, petitioner filed a petition for compensation under the National
Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 [the “Vaccine
Act” or “Program”]. The petition alleges that petitioner suffered injuries as a result of her
receipt of a “Pneunovax 23” [sic.] vaccine on June 19, 2012. For the reasons discussed
below, petitioner’s claim is hereby DISMISSED.
I. Procedural History
Although petitioner filed an exhibit list with her petition, none of the identified
records were filed. The only evidence filed in this case is petitioner’s affidavit which
states that petitioner was injured by a “Pneunovax 23 vaccination.” (ECF No. 1, p. 7.)
1 Because this unpublished decision contains a reasoned explanation for the action in this case, it will be
posted on the United States Court of Federal Claims' website, in accordance with the E-Government Act
of 2002, Pub. L. No. 107-347, § 205, 116 Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501
note (2006)). In accordance with Vaccine Rule 18(b), petitioner has 14 days to identify and move to
redact medical or other information, the disclosure of which would constitute an unwarranted invasion of
privacy. If, upon review, I agree that the identified material fits within this definition, I will redact such
material from public access.
2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for
ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. §
300aa (2006).

Case 1:15-vv-00632-UNJ Document 16 Filed 05/02/16 Page 2 of 4
Because the petition alleged injury from a vaccine not covered by the Vaccine
Program,3 an order to show cause was issued instructing petitioner to amend her
petition to allege injury from a Program-covered vaccine or otherwise show cause why
the petition should not be dismissed.4 (ECF No. 5.)
Subsequently, proceedings in this case were suspended first for 30 days to
accommodate petitioner’s counsel while he obtained a CM/ECF account (ECF No. 6.),
and then again for a further 45 days, on petitioner’s first motion for enlargement (ECF
No. 8; Order Granting Motion (Non-PDF), 8/31/2015). In support of the motion,
petitioner’s counsel cited personal issues unrelated to the instant case, including illness
and legal difficulties, that left him unable to timely file a response to the order to show
cause. (Id., p. 2.)
In a second motion for enlargement, petitioner’s counsel requested a further 60
days, or until December 15, 2015, to respond to the order to show cause originally
issued some four months prior. (ECF Nos. 11, 12.) Petitioner’s counsel indicated in the
second request that the enlargement of time was necessary “in order to verify the
precise vaccination given to Petitioner.” (ECF No. 12, p. 2.) He reported, however, that
his client had apparently severed contact and he has been unable to locate her to
secure HIPAA authorization.5 (Id., pp. 2-3.)
Petitioner’s counsel’s second motion for enlargement was granted and he was
allowed until December 15, 2015, to file a response to the court’s show cause order.
(See ECF No. 13.)
The court has been very generous in granting petitioner’s counsel multiple
enlargements to respond to the show cause order. As of December 15, 2015, petitioner
has had 179 days to formulate her response. This is more than adequate, particularly
given that petitioner need only introduce a claim that she was injured by a Program-
covered vaccine. The remaining elements of her claim could have been substantiated
at a later date. Contrary to counsel’s suggestion in his first motion for enlargement, the
requisite response is not “complex.” (ECF No. 8, p. 2.)
3 “There are two types of pneumococcal vaccines . . . pneumococcal conjugate and polysaccharide
vaccines.” Bundy v. HHS, No. 12-769v, 2014 WL 348852, at *1 (Fed. Cl. Spec. Mstr. Jan. 8, 2014.) Only
pneumococcal conjugate vaccines, routinely administered to children, are covered by the Vaccine
Program. Id.; see also Morrison v. HHS, No. 04-1683, 2005 WL 2008245, at *1 (Fed. Cl. Spec. Mstr. July
26, 2005)(describing how and when pneumococcal conjugate vaccines were added to the Vaccine
Table). The Pneumovax 23 vaccine is a polysaccharide vaccine and therefore not a vaccine set forth in
the Vaccine Injury Table. See Bundy, 2014 WL 348852, at *2; 42 C.F.R. § 100.3 (2011).
4 The order to show cause was issued by then Chief Special Master Vowell. This case was transferred to
the undersigned on September 9, 2015. (ECF No. 10.)
5 Counsel indicated that petitioner’s last known phone numbers were disconnected and she had not been
found at her last known address on multiple occasions. (Id.) Counsel reported, upon information and
belief, that petitioner may have moved from the Buffalo, New York, area to someplace in South Carolina.
(Id., p. 3.)

Case 1:15-vv-00632-UNJ Document 16 Filed 05/02/16 Page 3 of 4
Despite this, petitioner has allowed the December 15, 2015, show cause
deadline to lapse and has failed to file any response to the court’s order to show cause.
The undersigned’s most recent order granting an enlargement of time explicitly stated
that no further extension would be granted and that a failure to file a timely response to
the show cause order, including evidence of vaccination from a Program-covered
vaccine, would result in dismissal. (See ECF No. 13, pp. 1, 3.)
II. Legal Standard
The authority of special masters is limited by statute. The Vaccine Act vested
special masters with authority to award compensation only for injuries caused by certain
vaccines—those recommended for routine administration to children. See H.R. Rep. 99-
908, 1986 U.S.C.C.A.N. 6344 at 3. The vaccines initially covered by the Program were
those listed in section 14 of the Act—the original Vaccine Injury Table. As more
vaccines were recommended for routine administration to children by the Centers for
Disease Control and Prevention [“CDC”], the Secretary, Health and Human Services
[“HHS”] was directed to amend the Table for their inclusion. See § 14(c)(1); 42 C.F.R. §
100.3 (2011) (the current Table). Importantly, a tax is enacted on each vaccine listed
on the Table to provide funds for compensation for possible injury resulting from a
vaccine. The date the tax is enacted is the date a vaccine becomes a part of the
Vaccine Program. See 26 U.S.C. § 4131(a); see also Omnibus Budget Reconciliation
Act of 1993, Pub.L. No. 103–66, § 13632(a)(3), 107 Stat. 312 (1993).
Significant to this case, only some, but not all, pneumococcal vaccines are
included in the Vaccine Injury Table. See 42 C.F.R. § 100.3 (2011). “There are two
types of pneumococcal vaccines . . . pneumococcal conjugate and polysaccharide
vaccines.” Bundy v. HHS, No. 12-769v, 2014 WL 348852, at *1 (Fed. Cl. Spec. Mstr.
Jan. 8, 2014.) Only pneumococcal conjugate vaccines, routinely administered to
children, are covered by the Vaccine Program. Id.; see also Morrison v. HHS, No. 04-
1683, 2005 WL 2008245, at *1 (Fed. Cl. Spec. Mstr. July 26, 2005)(describing how and
when pneumococcal conjugate vaccines were added to the Vaccine Table). The
Pneumovax 23 vaccine is a polysaccharide vaccine and therefore not a vaccine set
forth in the Vaccine Injury Table. See Bundy, 2014 WL 348852, at *2; 42 C.F.R. § 100.3
(2011).
To be entitled to compensation under the Vaccine Act, a petitioner must
demonstrate that she received a vaccine set forth in the Vaccine Injury Table and that
she experienced an injury caused by that vaccine. See §11(c). Petitioner bears the
initial burden of demonstrating these elements by preponderant proof. See § 13(a)(1).
III. Discussion
To date, petitioner has completely failed to come forward with any evidence that
she was injured by a Program-covered vaccine. Her petition alleges that she was
injured by a Pneumovax 23 vaccine which is a polysaccharide pneumococcal vaccine
not include on the Vaccine Injury Table. (ECF No. 1, p. 1.) To the extent petitioner’s
counsel subsequently suggested that the exact vaccination petitioner received was not

Case 1:15-vv-00632-UNJ Document 16 Filed 05/02/16 Page 4 of 4
yet verified (see ECF No. 11, p. 2), petitioner was given additional time to file proof of
this suggestion. Petitioner failed to file any additional evidence. Indeed, the only
evidence in the record of this case is petitioner’s affidavit and that affidavit specifically
avers injury from the same non-covered vaccine alleged as causal in her petition. (See
ECF No. 1, pp. 6-7.)
In any event, petitioner’s failure to respond to the court’s order to show cause
constitutes a failure to prosecute and represents an independent basis for dismissal of
this petition. (See Vaccine Rule 21(b)(1).) Petitioner was specifically warned when her
second motion for enlargement was granted that no further extension would be allowed
and that failure to file a response by December 15, 2015, would result in dismissal of
her claim. (ECF No. 13, pp. 1, 3.)
IV. Conclusion
Petitioner has failed to demonstrate that she received a vaccine covered under
the Vaccine Program. This case is dismissed for failure to state a claim upon
which relief can be granted. This case is also dismissed for a failure to
prosecute. The clerk shall enter judgment accordingly.6
s/Nora Beth Dorsey
Nora Beth Dorsey
Chief Special Master
6 If petitioner wishes to bring a civil action, she must file a notice of election rejecting the judgment pursuant to 42
U.S.C. § 300aa-21(a) “not later than 90 days after the date of the court’s final judgment.”